Syncona led a €80m Series B round in iOnctura.

Syncona, an investment trust dedicated to life science investments, led a €80m Series B round in iOnctura, a clinical-stage biopharmaceutical company, with participation from EIC Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund. "This financing is validation of iOnctura's approach to developing precision cancer treatments with maximum clinical impact. These therapies have the potential to significantly prolong the healthspan of patients suffering with neglected cancer types, such as uveal melanoma. We are pleased to welcome our new investors Syncona and the EIC Fund alongside our existing strong syndicate. Their experience will be invaluable as we look to advance our pipeline and take iOnctura to its next stage of growth," Catherine Pickering, iOnctura CEO.